Eli Lilly Retatrutide Phase 3 Results at ADA 2026
Eli Lilly Retatrutide Phase 3: 28.3% Weight Loss Pushes Obesity Into a Portfolio War | Witfire Elite View Witfire Elite Pharma News Investments Stock Market Breaking Analysis 28.3 Pharma Market Case Study · Witfire Elite View Eli Lilly Retatrutide Phase 3 Results A 28.3% average weight loss at 80 weeks is the headline. But the real story is that Lilly…
Trending News
Pharma Stock Market News: US-Israel-Iran War Impact on Drug Supply Chains, Oil Prices and Healthcare Stocks
The stock market is now looking at the US-Israel-Iran conflict through a sharper…
Pharma Stock Market News: US-Israel-Iran War Impact on Drug Companies, Oil Prices, and Pharma Supply Chains
The US-Israel-Iran war is affecting pharma stocks, drug supply chains, logistics costs, cold-chain…
Lilly’s Germany Investment Cut: Why Pharma Capital Is Starting to Vote Against Policy Risk
Lilly’s Germany Investment Cut: Why Pharma Capital Is Starting to Vote Against Policy…
IQVIA Wegovy Pill Data and Oral GLP-1 Market Expansion
IQVIA Wegovy Pill Data and Oral GLP-1 Market Expansion | Witfire Elite View…
Editorial picks
Eli Lilly Retatrutide Phase 3 Results at ADA 2026
Eli Lilly Retatrutide Phase 3: 28.3% Weight Loss Pushes Obesity Into a Portfolio War | Witfire Elite View Witfire Elite Pharma News Investments Stock Market Breaking Analysis 28.3 Pharma Market Case Study · Witfire Elite View Eli Lilly Retatrutide Phase 3 Results A 28.3% average weight loss at 80 weeks…
Categories
Investments
business news
Entrepreneurship
Startups
2026
INSIGHTS FOR THE NEW PHARMA LEADERS
Witfire Elite brings focused perspectives on pharma growth, innovation, manufacturing, startups, and executive strategy.
Around The World
IQVIA Wegovy Pill Data and Oral GLP-1 Market Expansion
IQVIA Wegovy Pill Data and Oral GLP-1 Market Expansion | Witfire Elite View Witfire Elite Pharma Markets Case Studies Strategy Long Read Pharma Market Case Studies Witfire Elite View IQVIA Wegovy Pill Data Oral GLP-1 May Bring New Patients Into the Market IQVIA’s early Wegovy pill data suggests oral GLP-1 drugs may expand the obesity market by bringing in new…
Pharma News
Eli Lilly Retatrutide Phase 3 Results at ADA 2026
Eli Lilly Retatrutide Phase 3: 28.3% Weight Loss Pushes Obesity Into a Portfolio War | Witfire Elite View…
FTX-6058 and Pociredir: FDA’s PRC2 Risk View Hit a Promising Sickle Cell Drug
FTX-6058 and Pociredir: FDA’s PRC2 Risk View Hit a Promising Sickle Cell Drug | Witfire Elite View Witfire…
IQVIA Wegovy Pill Data and Oral GLP-1 Market Expansion
IQVIA Wegovy Pill Data and Oral GLP-1 Market Expansion | Witfire Elite View Witfire Elite Pharma Markets Case…